| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/10/2013 | US20130012540 Hepatitis C Virus Inhibitors |
| 01/10/2013 | US20130012539 Compositions and Methods for Treating Lysosomal Disorders |
| 01/10/2013 | US20130012538 Compositions and methods for the treatment of metabolic disorders |
| 01/10/2013 | US20130012537 3,8-diaminotetrahydroquinoline derivative |
| 01/10/2013 | US20130012536 Modulators of atp-binding cassette transporters |
| 01/10/2013 | US20130012535 Sustained-release solid preparation for oral use |
| 01/10/2013 | US20130012534 Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same |
| 01/10/2013 | US20130012533 Controlled release oxycodone compositions |
| 01/10/2013 | US20130012532 Cyclopropanecarboxylic acid derivative |
| 01/10/2013 | US20130012531 Treatment method |
| 01/10/2013 | US20130012530 New Positive allosteric modulators of nicotinic acetylcholine receptor |
| 01/10/2013 | US20130012529 Heterobicyclic carboxamides as inhibitors for kinases |
| 01/10/2013 | US20130012528 Novel derivatives of erlotinib |
| 01/10/2013 | US20130012527 Preq1 riboswitches and methods and compositions for use of and with preq1 riboswitches |
| 01/10/2013 | US20130012526 Oxazole derivatives useful as modulators of faah |
| 01/10/2013 | US20130012525 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| 01/10/2013 | US20130012524 Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
| 01/10/2013 | US20130012523 Pyrazinone derivatives, pharmaceutically acceptable salts thereof and their uses |
| 01/10/2013 | US20130012522 New derivatives of propargylamine having neuroprotective capacity for the treatment of alzheimer's and parkinson's diseases |
| 01/10/2013 | US20130012521 Apoptosis signal-regulating kinase inhibitors |
| 01/10/2013 | US20130012520 Trazodone and trazodone hydrochloride in purified form |
| 01/10/2013 | US20130012519 Biomarker Identifying the Reactivation of STAT3 After Src Inhibition |
| 01/10/2013 | US20130012518 Bicyclic compounds and their uses as dual c-src / jak inhibitors |
| 01/10/2013 | US20130012517 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012516 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
| 01/10/2013 | US20130012515 Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012514 Aminoalkyloxazole and aminoalkylthiazolecarboxylic acid amides as regeneration-promoting substances for sensory organs and post-mitotic tissue |
| 01/10/2013 | US20130012513 Hedgehog inhibitors |
| 01/10/2013 | US20130012512 P38 MAP kinase inhibitors |
| 01/10/2013 | US20130012511 Soluble guanylate cyclase activators |
| 01/10/2013 | US20130012510 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 |
| 01/10/2013 | US20130012509 Novel anxiolytic compounds |
| 01/10/2013 | US20130012508 Novel anxiolytic compounds |
| 01/10/2013 | US20130012507 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 01/10/2013 | US20130012506 Anti-infective pyrido (1,2-a) pyrimidines |
| 01/10/2013 | US20130012505 Benzonaphthyridinamines as autotaxin inhibitors |
| 01/10/2013 | US20130012504 Bi-functional quinoline analogs |
| 01/10/2013 | US20130012502 Pharmaceutical or Veterinary Antiviral Compositions |
| 01/10/2013 | US20130012501 Pyrimidinediamine kinase inhibitors |
| 01/10/2013 | US20130012500 Organic compounds |
| 01/10/2013 | US20130012499 Trpv4 antagonists |
| 01/10/2013 | US20130012498 5ht2c receptor modulators |
| 01/10/2013 | US20130012497 Methods for detecting adhd susceptibility and predicting severity and long term outcome of adhd symptoms |
| 01/10/2013 | US20130012496 Benzazepine compound |
| 01/10/2013 | US20130012495 5ht2c receptor modulators |
| 01/10/2013 | US20130012494 Cyclopropyl-fused-1,3-thiazepines as bace1 and/or bace2 inhibitors |
| 01/10/2013 | US20130012493 Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use |
| 01/10/2013 | US20130012492 Fused heterocyclic compounds as ion channel modulators |
| 01/10/2013 | US20130012491 Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
| 01/10/2013 | US20130012490 Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators |
| 01/10/2013 | US20130012489 Morpholinylquinazolines |
| 01/10/2013 | US20130012488 Benzoxepin pi3k inhibitor compounds and methods of use |
| 01/10/2013 | US20130012487 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors |
| 01/10/2013 | US20130012486 Combination steroid and glucocorticoid receptor antagonist therapy |
| 01/10/2013 | US20130012485 Organic compounds |
| 01/10/2013 | US20130012484 Petroleum jelly-free unguent compositions comprising vitamin d compounds and optionally steroidal anti-inflammatory agents |
| 01/10/2013 | US20130012483 Novel pharmaceutical composition for the treatment of neurodegenerative or neurovascular diseases |
| 01/10/2013 | US20130012482 Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine |
| 01/10/2013 | US20130012481 Crystalline forms of tigecycline hydrochloride |
| 01/10/2013 | US20130012480 Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same |
| 01/10/2013 | US20130012479 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012478 Dosage forms of bisphosphonates |
| 01/10/2013 | US20130012477 Derivatives of dillapiol and related monolignans and use thereof |
| 01/10/2013 | US20130012476 Compounds and compositions as protein kinase inhibitors |
| 01/10/2013 | US20130012475 Cosmetic and Pharmaceutical Composition Comprising N-Acetylglucosamine-6-Phosphate |
| 01/10/2013 | US20130012474 Cellulose Gel Formulations |
| 01/10/2013 | US20130012473 Combined use of phospholipid and sulfate groups-carrying polysaccharides for inhibiting metastatic spread |
| 01/10/2013 | US20130012472 Composition and methods of inhibiting gastrointestinal pathogen infection |
| 01/10/2013 | US20130012471 Means and methods for producing artificial capsular polysaccharides of neisseria meningitidis |
| 01/10/2013 | US20130012470 Antiviral compositions and methods of their use |
| 01/10/2013 | US20130012469 Liquid nucleotides/nucleosides-containing product |
| 01/10/2013 | US20130012468 Chemical compounds |
| 01/10/2013 | US20130012467 Bqc-g, a tumor-selective anti-cancer prodrug |
| 01/10/2013 | US20130012466 Colchicine neoglycosides and methods for their synthesis and use |
| 01/10/2013 | US20130012465 Bibw 2992 for use in the treatment of triple negative breast cancer |
| 01/10/2013 | US20130012464 Glycyrrhizinates of morphinan derivatives |
| 01/10/2013 | US20130012463 Identification of free-b-ring flavonoids as potent cox-2 inhibitors |
| 01/10/2013 | US20130012462 Receptor modulators exhibiting neuroprotective and memory enhancing activities |
| 01/10/2013 | US20130012460 Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
| 01/10/2013 | US20130012459 Composition for inhibiting the onset of arteriosclerosis and inhibition method |
| 01/10/2013 | US20130012458 7-hydroxy chromones as potent antioxidants |
| 01/10/2013 | US20130012455 Use of ARC for inhibiting cell death during liver failure |
| 01/10/2013 | US20130012444 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012443 Methods of treatment of central nervous system hemorrhage using protoporphyrin ix-fe compounds |
| 01/10/2013 | US20130012434 Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use |
| 01/10/2013 | US20130011903 Thymidine Kinase Mutants and Fusion Proteins Having Thymidine Kinase and Guanylate Kinase Activities |
| 01/10/2013 | US20130011902 Stimulation of the synthesis of the activity of an isoform of lysyl oxidase-like loxl for stimulating the formation of elastic fibers |
| 01/10/2013 | US20130011852 Compounds that interact with kinases |
| 01/10/2013 | US20130011498 Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate |
| 01/10/2013 | US20130011496 Cancer testis antigens as biomarkers in non-small cell lung cancer |
| 01/10/2013 | US20130011488 Systems, Methods, and Formulations for Treating Cancer |
| 01/10/2013 | US20130011486 Visual performance and/or macular pigmentation |
| 01/10/2013 | US20130011485 Magnetic nanomedicine for inhibiting/treating human prostate cancer |
| 01/10/2013 | US20130011484 Cannabinoid Receptor Binding Agents, Compositions, and Methods |
| 01/10/2013 | US20130011483 Formulations of mazindol |
| 01/10/2013 | US20130011482 Dual component medicament delivery system |
| 01/10/2013 | US20130011481 Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Formulations and Methods for Preparing and Using Same |
| 01/10/2013 | US20130011480 Cytotoxic therapy by proton flux modulation |
| 01/10/2013 | US20130011479 Double-layer pharmaceutical formulations containing opioid agonists and antagonists |
| 01/10/2013 | US20130011478 Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga) |